{"id":"ocr","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Breast tenderness"},{"rate":"5-15","effect":"Breakthrough bleeding"},{"rate":"2-5","effect":"Mood changes"},{"rate":"0.3-0.4","effect":"Venous thromboembolism"}]},"_chembl":null,"_dailymed":{"setId":"9da42362-3bb5-4b83-b4bb-b59fd4e55f0d","title":"OCREVUS (OCRELIZUMAB) INJECTION [GENENTECH, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"OCR works through combined hormonal contraception: the estrogen component suppresses follicle-stimulating hormone (FSH) to prevent follicle development, while the progestin inhibits luteinizing hormone (LH) surge to prevent ovulation. Additionally, the progestin thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.","oneSentence":"OCR is an oral contraceptive containing ethinylestradiol and norgestimate that prevents pregnancy by suppressing ovulation and altering cervical mucus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:50.090Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Contraception"},{"name":"Acne vulgaris (moderate)"},{"name":"Menorrhagia / heavy menstrual bleeding"}]},"trialDetails":[{"nctId":"NCT05285891","phase":"PHASE4","title":"Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-12","conditions":"Multiple Sclerosis","enrollment":123},{"nctId":"NCT07449429","phase":"","title":"A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2026-02-28","conditions":"Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Acute Coronary Syndromes, ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":10},{"nctId":"NCT07332468","phase":"NA","title":"Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-ASCVD)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01","conditions":"Atherosclerotic Cardiovascular Diseases","enrollment":790},{"nctId":"NCT07332494","phase":"NA","title":"Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01","conditions":"Coronary Heart Disease, Percutaneous Coronary Intervention","enrollment":792},{"nctId":"NCT07312019","phase":"NA","title":"Optimization of Medical Time in the Emergency Department: Impact of an AI-Based System on Prescription Entry","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2026-01","conditions":"Drug-related Iatrogenesis, Emergency Department, Artificial Intelligence","enrollment":770},{"nctId":"NCT07031531","phase":"NA","title":"Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-08-08","conditions":"Premature Coronary Heart Disease","enrollment":4900},{"nctId":"NCT03413371","phase":"NA","title":"Different Peribulbar Blocks With SPI-guided Anaesthesia for VRS (P&MSPIVRS)","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2018-04-26","conditions":"Vitreoretinal Surgeries, Postoperative Nausea and Vomiting, Postoperative Pain","enrollment":184},{"nctId":"NCT07181811","phase":"NA","title":"Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Anza Memon","startDate":"2025-09-30","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT06121349","phase":"","title":"WOE of Anti-CD20 Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-04","conditions":"Multiple Sclerosis","enrollment":157},{"nctId":"NCT06831071","phase":"","title":"Evaluation of Hypoxia in Primary Melanoma","status":"RECRUITING","sponsor":"Yana Najjar","startDate":"2025-04-09","conditions":"Melanoma","enrollment":50},{"nctId":"NCT06700226","phase":"NA","title":"AblaView® Unipolar PFA OCR-guided Feasibility Study - First in Man","status":"COMPLETED","sponsor":"Medlumics","startDate":"2024-09-08","conditions":"Paroxysmal AF","enrollment":10},{"nctId":"NCT03589742","phase":"NA","title":"Feasibility Study for Optically Guided Radiofrequency Ablation Catheter","status":"COMPLETED","sponsor":"Medlumics","startDate":"2017-06-24","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":4},{"nctId":"NCT00676715","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-07-17","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":220},{"nctId":"NCT05081700","phase":"","title":"A Systems Approach to Understanding Disease Processes in Multiple Sclerosis","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2020-05-11","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT05798260","phase":"","title":"T-Cell Mitochondrial Respiration Response to Ketone Monoester Supplement in Healthy Volunteers and COVID-19","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2024-06-30","conditions":"COVID-19 Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT02545868","phase":"PHASE3","title":"A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-27","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":102},{"nctId":"NCT06293586","phase":"NA","title":"Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-12-01","conditions":"Anesthesia, Local, Ophthalmopathy, Strabismus","enrollment":140},{"nctId":"NCT03389243","phase":"NA","title":"Paracetamol and Metamizole With SPI-guided Anaesthesia for VRS","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2018-01-15","conditions":"Vitreoretinal Surgeries, Postoperative Nausea and Vomiting, Postoperative Pain","enrollment":165},{"nctId":"NCT05950308","phase":"","title":"Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-05","conditions":"Multiple Sclerosis","enrollment":61},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT00673920","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-04-24","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT03375944","phase":"NA","title":"Utilisation of Telemedicine in Optimal Cardiac Rehabilitation Program in Patients After Myocardial Revascularization","status":"UNKNOWN","sponsor":"Pawel Buszman","startDate":"2018-03-28","conditions":"Coronary Artery Disease With Myocardial Infarction","enrollment":1000},{"nctId":"NCT02973581","phase":"NA","title":"SPI-directed Analgesia for Vitreoretinal Surgeries","status":"COMPLETED","sponsor":"Medical University of Silesia","startDate":"2016-02","conditions":"Vitreoretinal Surgeries, Postoperative Nausea and Vomiting, Postoperative Pain","enrollment":176},{"nctId":"NCT01765361","phase":"","title":"Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2012-09","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT00743509","phase":"PHASE2","title":"A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2008-08","conditions":"Osteosarcoma","enrollment":49},{"nctId":"NCT01463657","phase":"PHASE1, PHASE2","title":"Split-face Comparison Study to Assess ELAPR Compared to Juvéderm® for the Treatment of Nasolabial Folds","status":"COMPLETED","sponsor":"Elastagen Pty Ltd","startDate":"2011-11","conditions":"Aging","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3006,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RO4964913, PRO70769, rhuMAb 2H7"],"phase":"marketed","status":"active","brandName":"OCR","genericName":"OCR","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OCR is an oral contraceptive containing ethinylestradiol and norgestimate that prevents pregnancy by suppressing ovulation and altering cervical mucus. Used for Contraception, Acne vulgaris (in females), Menorrhagia / heavy menstrual bleeding.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}